Hosted on MSN

Ohtuvayre: The First Novel COPD Treatment Approved in Over a Decade

Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...
Hosted on MSN

Environmentally Friendlier COPD Inhaler May Also Be More Effective

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...
EurekAlert!

Inhaler misuse leads to mismanagement of COPD symptoms, increased exacerbations

MIAMI (August 20, 2024) – Inhaler misuse leading to inadequate medication delivery impacts a person’s ability to manage symptoms of chronic obstructive pulmonary disease (COPD), and additional ...
Medscape

Majority of Hospitalized Patients With COPD Misuse Inhalers

Approximately two thirds of hospitalized adults with chronic obstructive pulmonary disease (COPD) received suboptimal treatment with inhalers, mainly resulting from errors, based on data from 96 ...
News Medical

Widespread inhaler misuse in COPD patients: Need for training

Chronic obstructive pulmonary disease (COPD) is a chronic lung condition characterized by loss of lung elasticity, which leads to dysfunctional gaseous exchange. COPD is the third leading cause of ...
News Medical

Study finds no clinical advantage of budesonide inhaler over fluticasone in COPD

The researchers evaluated budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol in preventing COPD exacerbations and pneumonia hospitalizations in real-world settings. They ...